Lifecore Biomedical, Inc. LFCR Temporary Equity Liquidation Preference

Temporary Equity Liquidation Preference at other companies

OS TherapiesOSTX

$2.5M0.0%

Envoy MedicalCOCH

$391K—

Nextdoor Holdings, Inc.NXDR

$0—

OS TherapiesOSTX

$1.07M-77.7%

Apollo Global ManagementAPO

$0—

ORI

Origin Investment Corp I Ordinary SharesORIQ

6.9M—

Other financials

Income statement

See full

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Balance sheet

See full

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Cash flow

See full

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Valuation

See full

Market cap$196.92M-37.3%

Enterprise value$333.06M+6.3%

P/S1.6×+0.5×

Profitability

See full

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Returns & leverage

See full

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TemporaryEquityLiquidationPreference.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s temporary equity liquidation preference.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s temporary equity liquidation preference?: Lifecore Biomedical, Inc. (LFCR) reported temporary equity liquidation preference of $49.26M in Q1 2026.